Analytical Quality by Design Approach for a Stability-Indicating Method to Determine Apixaban and Its Related Impurities

被引:11
作者
Ellwanger, Jessica B. [1 ]
Wingert, Nathalie Ribeiro [1 ]
Volpato, Nadia Maria [1 ]
Garcia, Cassia Virginia [1 ]
Schapoval, Elfrides E. S. [1 ]
Steppe, Martin [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Lab Pharmaceut Qual Control, Porto Alegre, RS, Brazil
关键词
Apixaban; Quality-by-design; AQbD; Experimental design; Drug impurities; ORALLY BIOAVAILABLE INHIBITOR; FACTOR XA INHIBITOR; HIGHLY POTENT; HPLC METHOD; DRUG; DEGRADATION; IDENTIFICATION; VALIDATION; TICAGRELOR; SAFETY;
D O I
10.1007/s10337-019-03815-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Quality by Design (QbD) is a systematic approach that takes predefined objectives and emphasizes process understanding and control. Analytical QbD (AQbD) is widely used when it comes to the development and optimization of analytical methods. Since impurities and contaminants may be present in the pharmaceutical product, current regulatory guidelines recommend monitoring these substances. Thus, the aim of this work was to develop and validate a fast and sensitive stability indicating method by high-performance liquid chromatography (HPLC) for the simultaneous determination of apixaban and three synthesis impurities using AQbD approach. Experiments were designed and assessed on MODDE 11 (Umetrics, Sweden) software and carried out in a Shimadzu LC-20A Prominence HPLC-DAD at 220 nm. Design of experiments was applied to achieve the optimum conditions through response surface methodology with four quantitative critical method parameters (CMPs): column temperature, flow rate, mobile phase pH and organic percentage. Besides, the chromatographic column was the fifth CMP taken as a qualitative variable. The HPLC method was established using an Inertsil CN-3 column at the temperature of 30 degrees C. The mobile phase consisted of methanol and water (50.2:49.8) at a flow rate of 1.015 mL/min with no pH adjustment. In order to confirm method selectivity excipients mixture was evaluated, as well as hydrolytic, photolytic, thermolytic, and oxidative conditions. The method was also validated for sensitivity (LOQ 0.5 mu g/mL, LOD 0.01-0.05 mu g/mL for impurities), linearity (concentration range 1-35 mu g/mL for APX and 0.5-10 mu g/mL for impurities, r > 0.999), precision (RSD <= 10%) and accuracy between levels (RSD < 3.0 for APX and < 4.0% for impurities). The application of AQbD led to a well-understood and validated analytical method that provided assured separation of APX and all significant impurities, turning it into a powerful decision-making tool for the analytical methodologies development.
引用
收藏
页码:65 / 75
页数:11
相关论文
共 39 条
[1]   Apixaban: A New Player in the Anticoagulant Class [J].
Agrawal, Ritesh ;
Jain, Pratima ;
Dikshit, S. N. .
CURRENT DRUG TARGETS, 2012, 13 (06) :863-875
[2]  
[Anonymous], 2009, Pharmaceutical Development Q8(R2)
[3]  
[Anonymous], 2005, Validation of analytical procedures: Text and methodology Q2 (R1)
[4]  
[Anonymous], 2005, ICH HARM TRIP GUID Q
[5]   Strategies for the investigation and control of process-related impurities in drug substances [J].
Argentine, Mark D. ;
Owens, Paul K. ;
Olsen, Bernard A. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (01) :12-28
[6]   Design Space of Pharmaceutical Processes Using Data-Driven-Based Methods [J].
Boukouvala, Fani ;
Muzzio, Fernando J. ;
Ierapetritou, Marianthi G. .
JOURNAL OF PHARMACEUTICAL INNOVATION, 2010, 5 (03) :119-137
[7]   HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation products [J].
Bueno, Livia Maronesi ;
Manoel, Joanna Wittckind ;
Alves Giordani, Camila Ferrazza ;
Loureiro Mendez, Andreas Sebastian ;
Volpato, Nadia Maria ;
Scherman Schapoval, Elfrides Eva ;
Steppe, Martin ;
Garcia, Cassia Virginia .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 97 :22-29
[8]  
Cavazzuti Marco, 2012, OPTIMIZATION METHODS, P13
[9]  
DC Montgomery, 2012, DESIGN ANAL EXPT LIV
[10]   Improved quality-by-design compliant methodology for method development in reversed-phase liquid chromatography [J].
Debrus, Benjamin ;
Guillarme, Davy ;
Rudaz, Serge .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 84 :215-223